Drugs Associated With Anemia
Multiple medication classes can cause anemia through bone marrow suppression, hemolysis, or impaired RBC production via folate or vitamin B12 pathways. [1, 2] Drug-induced anemia can present as isolated anemia or as part of broader hematologic toxicity (eg, neutropenia or pancytopenia). [2, 3]
Major Pathophysiologic Categories
- Bone marrow suppression (reduced RBC production) from cytotoxic or marrow-toxic drugs. [2, 4]
- Drug-induced immune hemolytic anemia from drug-triggered immune RBC destruction. [3, 5]
- Hemolysis from oxidation or toxic metabolite effects, including in settings such as G6PD deficiency. [3, 5]
- Megaloblastic anemia from impaired folate or vitamin B12 absorption, metabolism, or utilization. [1, 6]
Medication Classes Known to Cause Anemia (Representative Examples)
Bone Marrow Suppression / Reduced RBC Production
- Antineoplastic chemotherapy and other cytotoxic drugs. [4]
- Antirheumatic drugs. [2]
- Antithyroid medications. [2]
- Antituberculous drugs. [2]
- NSAIDs and anticonvulsants have been implicated in drug-induced aplastic anemia and broader marrow suppression syndromes. [2]
Hemolytic Anemia
- Drug-induced immune hemolytic anemia with listed reports including methyldopa and selected beta-lactam antibiotics (including cefotetan, ceftriaxone). [3]
- Oxidative hemolysis or related toxic mechanisms reported with medications including dapsone, nitrofurantoin, and ribavirin. [3]
- Dapsone is associated with hemolytic anemia. [7]
Megaloblastic Anemia (Folate / Vitamin B12 Pathways)
The following drugs are commonly associated with macrocytosis and megaloblastic anemia patterns that can progress to clinically significant anemia:
- Hydroxyurea. [6]
- Methotrexate. [6]
- Zidovudine. [6]
- Azathioprine. [6]
- Valproic acid. [6]
- Phenytoin. [6]
Medication Selection Algorithm
Assessment of a medication-related anemia typically follows mechanism matching.
- Suspected impaired RBC production favors drugs associated with marrow suppression (eg, cytotoxic/antineoplastic agents, antirheumatic drugs, antithyroid drugs, antituberculous drugs, NSAIDs, anticonvulsants). [2, 4]
- Suspected hemolysis favors drugs associated with immune hemolytic anemia (eg, methyldopa, selected beta-lactams) or oxidation/toxic hemolysis (eg, dapsone, nitrofurantoin, ribavirin). [3, 7]
- Suspected megaloblastic anemia favors drugs linked to folate or vitamin B12 interference (eg, hydroxyurea, methotrexate, zidovudine, azathioprine, valproic acid, phenytoin). [1, 6]
Key Evidence Supporting These Associations
- Drug-induced megaloblastic anemia commonly results from interfering with folate or vitamin B12 absorption, altering vitamin B12 metabolism, or blocking pathways requiring these vitamins. [1]
- Drug-induced immune hemolytic anemia is a recognized mechanism in which medications trigger immune attack against RBCs. [5]
- Reviews of drug-induced hematologic syndromes describe anemia presentations including hemolytic anemia, aplastic anemia, and megaloblastic anemia due to diverse drug toxicities. [2]
Initiation Thresholds or Timing Patterns
- Many drug-induced anemias are toxicity-related and can occur after initiation and during ongoing exposure, including syndromic patterns that emerge alongside other cytopenias. [2, 3]
- Zidovudine is associated with hematologic toxicity including anemia in labeled clinical experience. [8]
Common Pitfalls to Avoid
- Attributing anemia solely to dilutional or chronic causes without evaluating medication-associated mechanisms when exposure includes marrow-toxic, hemolysis-associated, or folate/B12-interfering drugs. [2, 5]
- Failing to consider immune hemolysis when anemia is accompanied by hemolysis-compatible laboratory findings, given drug-triggered immune RBC destruction as a mechanism. [5]
Practical Diagnostic Targets When Suspecting Drug-Induced Anemia
- Hemolysis assessment is indicated to differentiate drug-induced immune hemolytic anemia from reduced production syndromes. [5]
- Megaloblastic anemia patterns should trigger review of drugs associated with folate or vitamin B12 pathway disruption. [1, 6]
- Drug-toxicity syndromes should prompt review for accompanying hematologic abnormalities described in drug-induced hematologic syndromes. [2, 3]